Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

Status:
Unknown status

Trial end date:
2017-07-01

Target enrollment:

Participant gender:

This is a efficacy and safety study of imatinib Mesylate Capsule as First line treatment in patients with chronic phase of Chronic Myeloid Leukemia.

Phase 4

Cttq

Ruijin Hospital

Imatinib Mesylate